Product Description
Fentanyl is a synthetic opioid that is 80-100 times stronger than morphine. Pharmaceutical fentanyl was developed for pain management treatment of cancer patients, applied in a patch on the skin. Because of its powerful opioid properties, Fentanyl is also diverted for abuse. Fentanyl is added to heroin to increase its potency, or be disguised as highly potent heroin. (Sourced from: https://www.dea.gov/factsheets/fentanyl)
Mechanisms of Action: OPR Agonist,NMDA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Transdermal,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pain Unspecified | Morphine Dependence | Migraine Disorders | Acute Pain | Breakthrough Pain | Cancer Pain | Headache | Pain Unspecified | Pain, Postoperative | Morphine Dependence | Oncology Unspecified | Migraine Disorders | Acute Pain | Cancer Pain | Headache | Pain Unspecified | Pain, Postoperative | Morphine Dependence | Oncology Unspecified | Migraine Disorders | Acute Pain | Breakthrough Pain | Cancer Pain | Headache | Pain Unspecified | Pain, Postoperative | Morphine Dependence | Oncology Unspecified | Migraine Disorders | Acute Pain | Breakthrough Pain | Cancer Pain | Headache | Pain Unspecified | Pain, Postoperative | Morphine Dependence | Oncology Unspecified | Migraine Disorders | Acute Pain | Cancer Pain | Headache | Pain Unspecified | Pain, Postoperative | Morphine Dependence | Oncology Unspecified
Known Adverse Events: Dizziness | Headache | Insomnia | Hyperhidrosis | Anorexia | Constipation | Diarrhea | Common Cold | Dyspnea | Depressive Disorder | Confusion | Asthenia | Anemia | Dehydration | Edema
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Egypt
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Abdominal Pain|Morphine Dependence|Other|Pain, Postoperative|Visceral Pain
Phase 2: Anesthesia Related|Breakthrough Pain|Cancer Pain|Oncology Unspecified|Pain Unspecified
Phase 1: Acute Pain|Low Back Pain|Mobility Limitation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Parallel group, multi-center study of Fentanyl Nasal Spray in patients with postoperative pain | P3 |
Active, not recruiting |
Morphine Dependence|Visceral Pain|Abdominal Pain|Pain, Postoperative |
2024-03-20 |
|
| ZK06 | P2 |
Completed |
Cancer Pain|Breakthrough Pain |
2023-03-15 |
32% |
| NIRVANA | P1 |
Completed |
Pain, Postoperative|Low Back Pain|Mobility Limitation|Acute Pain |
2022-02-01 |
43% |
| CTR20210946 | P3 |
Not yet recruiting |
Other |
None |